Table 1 The characteristics of enrolled subjects with and without HCV Ab seropositivity.
HCV Ab ( +) N = 85 | HCV Ab (‒) N = 1673 | P | |
|---|---|---|---|
Age (years) | 69 ± 8 | 66 ± 9 | 0.002 |
Male, n (%) | 35 (41.2) | 960 (57.4) | 0.005 |
Hypertension, n (%) | 69 (81.2) | 1312 (78.4) | 0.640 |
CVD history, n (%) | 56 (65.9) | 1064 (63.6) | 0.755 |
Diabetes duration (years) | 12 ± 8 | 13 ± 8 | 0.712 |
BMI (kg/m2) | 25.9 ± 4.4 | 25.9 ± 4.1 | 0.954 |
Systolic BP (mm Hg) | 139 ± 17 | 133 ± 18 | 0.004 |
Diastolic BP (mm Hg) | 75 ± 10 | 75 ± 11 | 0.822 |
Fasting glucose (mmol/L) | 7.5 ± 2.2 | 7.4 ± 2.0 | 0.677 |
HbA1c (%) | 7.0 ± 1.0 | 7.0 ± 1.1 | 0.959 |
Total cholesterol (mmol/L) | 3.9 ± 0.7 | 3.9 ± 0.8 | 0.561 |
LDL cholesterol (mmol/L) | 2.1 ± 0.6 | 2.1 ± 0.7 | 0.866 |
HDL cholesterol (mmol/L) | 1.4 ± 0.4 | 1.3 ± 0.4 | 0.236 |
Triglycerides (mmol/L) | 2.8 ± 1.5 | 3.2 ± 2.5 | 0.218 |
ALT (U/L) | 24 ± 17 | 25 ± 19 | 0.797 |
eGFR (mL/min/1.73 m2) | 68 ± 20 | 73 ± 22 | 0.034 |
UACR (mg/g) | 274 ± 611 | 123 ± 433 | 0.002 |
ABI | 1.1 ± 0.1 | 1.1 ± 0.1 | 0.461 |
Use of antiplatelet drugs, n (%) | 19 (22.4) | 431 (25.8) | 0.565 |
Use of statins, n (%) | 64 (75.3) | 1364 (81.5) | 0.196 |
Use of antihypertensive drugs, n (%) | 49 (57.6) | 842 (50.3) | 0.228 |
Use of ACE inhibitors or ARBs, n (%) | 33 (38.8) | 592 (35.4) | 0.596 |
Insulin therapy, n (%) | 25 (29.4) | 325 (19.4) | 0.035 |
Oral antihyperglycemic drugs, n (%) | 78 (91.8) | 1596 (95.4) | 0.204 |
Insulin secretagogues, n (%) | 24 (28.2) | 528 (31.6) | 0.600 |
Metformin, n (%) | 29 (34.1) | 634 (37.9) | 0.558 |
DPP4 inhibitors, n (%) | 44 (51.8) | 844 (50.4) | 0.900 |
SGLT2 inhibitors, n (%) | 26 (30.6) | 527 (31.5) | 0.955 |
Thiazolidinediones, n (%) | 26 (30.6) | 593 (35.4) | 0.425 |
α-Glucosidase inhibitors, n (%) | 8 (9.4) | 82 (4.9) | 0.112 |
